Posted in | News | Nanomedicine

Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference at 5:45 p.m. EDT on Tuesday, September 14, 2010, at the Palace Hotel in New York, NY.

Dr. Anzalone will be discussing the Company and its increased focus on its nanomedicine portfolio, including clinical results.

Source: http://www.arrowheadresearch.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, February 13). Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine. AZoNano. Retrieved on December 04, 2024 from https://www.azonano.com/news.aspx?newsID=19415.

  • MLA

    Arrowhead Pharmaceutical. "Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine". AZoNano. 04 December 2024. <https://www.azonano.com/news.aspx?newsID=19415>.

  • Chicago

    Arrowhead Pharmaceutical. "Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine". AZoNano. https://www.azonano.com/news.aspx?newsID=19415. (accessed December 04, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine. AZoNano, viewed 04 December 2024, https://www.azonano.com/news.aspx?newsID=19415.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.